ResearcherUniversity of Campania "Luigi Vanvitelli"No recent work listed
Michele Orditura
Matched on ORCID iD 0009-0005-6517-0136; OpenAlex author ID A5028284107. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper
Papers 5
- Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. Co-author DOI 10.3390/ijms21082814↗
- Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment. Co-author DOI 10.1007/s12032-019-1306-9↗
- Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propen… Co-author DOI 10.1155/2018/2373868↗
- NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. Last author DOI 10.1186/s12885-016-2671-9↗
- Targeting EGFR in pancreatic cancer treatment. Co-author DOI 10.2174/138945012800564158↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ferdinando De Vita · 4 shared papers, 2016–2020 · strength 0.31
- Paper Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. DOI 10.3390/ijms21082814↗
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Luca Pompella · 3 shared papers, 2018–2020 · strength 0.26
- Paper Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis. DOI 10.3390/ijms21082814↗
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Angelica Petrillo · 3 shared papers, 2016–2019 · strength 0.20
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Paper NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical … DOI 10.1186/s12885-016-2671-9↗
- Annalisa Pappalardo · 2 shared papers, 2019–2020 · strength 0.20
- Fortunato Ciardiello · 3 shared papers, 2012–2019 · strength 0.17
- Paper Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabi… DOI 10.1007/s12032-019-1306-9↗
- Paper NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical … DOI 10.1186/s12885-016-2671-9↗
- Paper Targeting EGFR in pancreatic cancer treatment. DOI 10.2174/138945012800564158↗
- Teresa Troiani · 3 shared papers, 2012–2018 · strength 0.15
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Paper NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical … DOI 10.1186/s12885-016-2671-9↗
- Paper Targeting EGFR in pancreatic cancer treatment. DOI 10.2174/138945012800564158↗
- Jole Ventriglia · 2 shared papers, 2016–2018 · strength 0.12
- Paper Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with N… DOI 10.1155/2018/2373868↗
- Paper NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical … DOI 10.1186/s12885-016-2671-9↗
- Floriana Morgillo · 2 shared papers, 2012–2018 · strength 0.10
- Marisol Huerta · 1 shared paper, 2018 · strength 0.07
- Andrès M.R. Cervantes · 1 shared paper, 2018 · strength 0.07
- Guido Giordano · 1 shared paper, 2016 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.